ESTREVA 0,1 %, gel, ANDROGEL 16,2 mg/g, gel, PROVAMES 1 mg, comprimé pelliculé
P170923J
Phase 3 small_molecule active
Quick answer
ESTREVA 0,1 %, gel, ANDROGEL 16,2 mg/g, gel, PROVAMES 1 mg, comprimé pelliculé for gender dysphoria is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- gender dysphoria
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active